Core Viewpoint - The company achieved significant financial growth, marking its first annual profit with a notable increase in revenue and net profit compared to the previous year [1] Financial Performance - Total revenue reached 13.0415 billion RMB, representing a year-on-year increase of 38.4% [1] - The company reported an IFRS net profit of 814 million RMB, a substantial improvement from a loss of 94.63 million RMB in 2024 [1] - Product revenue amounted to 11.896 billion RMB, up 44.6% year-on-year, driven by a strong position in the oncology sector and rapid expansion of the product line [1] - Licensing fee income decreased to 957 million RMB from 1.1 billion RMB in 2024, yet overall revenue growth contributed to enhanced profitability [1] - Non-IFRS net profit surged to 1.723 billion RMB, reflecting a remarkable year-on-year growth of 419.6% [1]

Core Viewpoint - The company, Innovent Biologics, reported a significant revenue growth of 38.4% year-on-year, reaching 13.0415 billion RMB for the fiscal year ending December 31, 2025, marking its first complete year of profitability with a net profit of 813.6 million RMB, indicating a historic breakthrough in business scale, profitability, and global innovation [3]. Group 1: Financial Performance - Total revenue for the fiscal year ending December 31, 2025, was 13.0415 billion RMB, reflecting a year-on-year growth of 38.4% [3]. - The company achieved a net profit of 813.6 million RMB under IFRS measurement, marking its first complete year of profitability [3]. Group 2: Strategic Developments - 2025 is highlighted as a milestone year for the company, achieving historic breakthroughs in business scale, profitability, and global innovation [3]. - The company has implemented a "dual-drive" strategic upgrade, leading in oncology and contributing to new growth through a comprehensive product line [3]. Group 3: Product Portfolio Expansion - The product portfolio has expanded to 18 marketed products, with 12 included in China's National Reimbursement Drug List (NRDL) [4]. - The company successfully launched several innovative products in the oncology field, solidifying its leading position in cancer treatment in China [4]. - New growth engines have been established through the commercialization of products such as Xin'ermei (Marsutide Injection) and Xinbimen (Trolizumab Injection) [4]. Group 4: Regulatory Developments - The 2025 updated NRDL, effective from January 1, 2026, includes a new indication for Daborushu (Sintilimab Injection) and adds several new products to the list, enhancing the company's market presence [4].

Core Viewpoint - The company, Innovent Biologics (01801), reported a total revenue of 13.0415 billion RMB for the year ending December 31, 2025, reflecting a year-on-year growth of 38.4%, marking its first complete year of profitability with a net profit of 813.6 million RMB under IFRS standards [1] Group 1: Financial Performance - Total revenue reached 13.0415 billion RMB, a 38.4% increase year-on-year [1] - Achieved a net profit of 813.6 million RMB, indicating a significant milestone in profitability [1] - The year 2025 is described as a milestone year for the company, showcasing historic breakthroughs in business scale, profitability, and global innovation [1] Group 2: Product Portfolio and Market Position - The product portfolio expanded to 18 marketed products, with 12 included in China's National Reimbursement Drug List (NRDL) [2] - Successful launches of innovative products in the oncology field, including Aorin (Leratinib), Daberu (Dabrafenib), Jiapali (Pimodivir), and Daberxin (Ipilimumab), solidifying the company's leading position in cancer treatment in China [2] - The company has developed new growth engines with products like Xin'ermei (Masitinib), Xinbile (Tocilizumab), and Xinbimin (Tafasitamab), contributing to its commercial expansion [2] Group 3: Strategic Developments - The company has advanced three innovative assets to or nearing global Phase III clinical development, enhancing its pipeline [1] - Multiple strategic collaborations have been established to accelerate the release of global pipeline innovation value [1] - The 2025 updated NRDL, effective from January 1, 2026, includes new indications for Daberu (Sintilimab) and adds several other products to the list, further expanding market access [2]

Core Viewpoint - The company achieved significant financial growth in the past year, with a notable increase in total revenue and a turnaround in net profit, indicating strong operational performance and potential for future growth [1] Financial Performance - The company reported total revenue of RMB 13.0415 billion, representing a year-on-year increase of 38.4% [1] - The International Financial Reporting Standards (IFRS) net profit reached RMB 813.6 million, recovering from a loss of RMB 94.63 million in the previous year [1] - The Non-IFRS net profit surged to RMB 1.7231 billion, marking a substantial year-on-year growth of 419.6% [1]

Core Viewpoint - The company achieved a significant milestone by surpassing RMB 10 billion in total revenue for the first time, marking a 38.4% year-on-year growth, and has entered a new era of sustainable profitability with its first annual profit [1] Financial Performance - Total revenue reached RMB 13,041.5 million for the year ending December 31, 2025, with a year-on-year increase of 38.4% [1] - The company reported a net profit of RMB 813.6 million under IFRS and a Non-IFRS net profit of RMB 1,723.1 million, up from RMB 331.6 million in 2024 [1] - Non-IFRS EBITDA rose to RMB 1,990.7 million compared to RMB 411.6 million in 2024, driven by strong revenue growth and improved operational efficiency [1] Revenue Breakdown - Product revenue amounted to RMB 11,895.9 million, reflecting a 44.6% increase, primarily due to a leading position in the oncology sector and rapid expansion of the product line [1] - Licensing fee revenue was RMB 957.3 million, becoming a significant income source as the company deepens strategic collaborations and expands its pipeline [1] Research and Development - R&D expenditure was RMB 2,624.2 million, slightly down from RMB 2,681.1 million in 2024, indicating continued strategic investment in late-stage assets and early pipeline development [2] - The company is advancing its next-generation innovative pipeline into global development, showcasing strong execution in the R&D field [2]

Financial Performance - Total revenue for the year ended December 31, 2025, reached RMB 13,041.5 million, a year-on-year increase of 38.4% compared to RMB 9,421.9 million in 2024[4]. - Gross profit for the same period was RMB 11,285.5 million, up 42.6% from RMB 7,911.7 million in 2024, with a gross margin of 86.5%[4][7]. - The company achieved its first annual profit, reporting a net profit of RMB 813.6 million, compared to a loss of RMB 94.6 million in 2024[5][7]. - Non-IFRS net profit surged to RMB 1,723.1 million, a significant increase of 419.6% from RMB 331.6 million in 2024[4][8]. - Non-IFRS EBITDA for the year was RMB 1,990.7 million, compared to RMB 411.6 million in 2024, reflecting a growth of 383.7%[4][8]. - The company reported a net profit of approximately RMB 813.6 million under IFRS, marking a structural shift in profitability[23]. - The company has entered a phase of profitability, supported by rapid growth and improved operational efficiency[23]. Revenue Breakdown - Product revenue reached RMB 11,895.9 million, a 44.6% increase from RMB 8,227.9 million in 2024, driven by strong performance in the oncology sector[7]. - Revenue from pharmaceutical product sales for 2025 reached RMB 11,895,929, an increase of 44.5% compared to RMB 8,227,869 in 2024[168]. - Revenue from customer contracts for the year ended December 31, 2025, was RMB 13,041.5 million, an increase from RMB 9,421.9 million in 2024, representing a growth of approximately 38%[111]. - Revenue from the Chinese market in 2025 was RMB 12,069,480, up 34.5% from RMB 8,983,416 in 2024[170]. Research and Development - Research and development expenses for the year were RMB 2,624.2 million, slightly down from RMB 2,681.1 million in 2024, indicating continued strategic investment in late-stage assets[7]. - The company has advanced 11 new molecules to the IND preparation stage for clinical trials by 2025, supporting long-term sustainable growth[13]. - The company is committed to advancing its research and development efforts, focusing on innovative cancer therapies and expanding its global footprint[31]. - The company has published high-quality R&D data in top scientific journals, including NEJM and Nature, showcasing its research capabilities[18]. Clinical Trials and Product Development - Three core innovative assets are entering or about to enter global Phase III clinical trials, targeting a combined market size exceeding USD 60 billion[12]. - The company has successfully launched multiple innovative products in the oncology field, further solidifying its leading position in cancer treatment in China[10]. - The company has multiple products approved for global markets, including Darbuxu® (Sintilimab Injection) for various cancers such as non-small cell lung cancer and liver cancer[31]. - The company is conducting multiple international multi-center Phase I clinical studies based on its next-generation ADC platforms, including IBI3009 and IBI3001[14]. - IBI363 is expected to present results from three Phase I PoC studies at the 2025 ASCO, demonstrating tolerable safety and breakthrough efficacy in cold tumors and IO-resistant tumors[80]. Strategic Partnerships and Collaborations - The company has established a global strategic collaboration with Takeda Pharmaceutical, receiving a $1.2 billion upfront payment and is eligible for up to approximately $10.2 billion in milestone payments[15]. - The company achieved a strategic global collaboration with Takeda Pharmaceuticals, receiving a cash upfront payment of USD 1.1 billion and a USD 100 million equity investment[113]. - The company established diverse global partnerships, including a milestone collaboration with Takeda Pharmaceuticals, expected to generate over USD 1.6 billion in upfront payments[24]. Market Expansion and Future Goals - The company aims to establish itself as a leading global biopharmaceutical enterprise over the next five years, supported by a strong business foundation[6]. - The company aims to become a top-tier global biopharmaceutical enterprise by 2030, supported by strategic partnerships and innovative pipeline development[9]. - The company plans to accelerate its globalization strategy by establishing a fully integrated operational capability and expanding its global team through strategic partnerships[27]. - The goal is to have at least five molecules in global MRCT Phase III by 2030, leveraging a unique "East-West dual-engine" R&D advantage[26]. Financial Position and Assets - Total current assets increased to RMB 22,013.3 million as of December 31, 2025, from RMB 10,272.8 million as of December 31, 2024[126]. - Total assets as of December 31, 2025, amounted to RMB 28,961.3 million, up from RMB 17,233.7 million in 2024[159]. - The company's cash and cash equivalents increased to RMB 17,344.7 million in 2025, compared to RMB 7,508.2 million in 2024[159]. - The company's total equity increased to RMB 19,356.2 million in 2025, up from RMB 13,117.7 million in 2024[160]. Operational Efficiency - Sales and marketing expenses amounted to RMB 5,712.9 million, representing 43.8% of total revenue, down from 46.1% in 2024, showcasing improved operational efficiency[7]. - Administrative and other expenses were RMB 927.0 million for the year ended December 31, 2025, up from RMB 738.0 million for the year ended December 31, 2024, with the percentage of total revenue decreasing from 7.8% to 7.1%[118]. Governance and Compliance - The company has established an audit committee, nomination committee, compensation committee, and strategic committee to enhance governance[147]. - The company has no significant litigation or arbitration pending as of December 31, 2025[151]. - The board did not recommend a final dividend for the year ended December 31, 2025[138].

Innovent Biologics 2025 Annual Results From China Leadership to Global Premier: Innovent's Definitive Path to Value and Growth March 2026 Agenda and Speakers | Business Review and Outlook | Dr. Michael Yu | Founder, Chairman of the Board, CEO | | --- | --- | --- | | R&D Highlight Updates | Dr. Hui Zhou | Chief R&D Officer, Oncology | | | Dr. Lei Qian | Chief R&D Officer, General Biomedicine | | Financials and Summary | Ms. Rachel You | Chief Financial Officer | | Q&A | Management Team | | Confidential Copyr ...

Group 1 - The collaboration between Lao Bai Xing Pharmacy and Innovent Biologics aims to enhance the commercialization and accessibility of the innovative drug Ma Shidu Te (信尔美®) for metabolic disease patients [2][3] - The partnership is based on the principle of "complementary advantages and win-win cooperation," integrating Innovent's R&D strengths with Lao Bai Xing's extensive retail network and professional service system [3] - Lao Bai Xing Pharmacy has over 9,000 stores, each featuring a section for original research drugs, and has already listed several innovative drugs, including Ma Shidu Te, in some of its outlets [3] Group 2 - The demand for disease management in China is increasing due to the large patient base for metabolic diseases, with GLP-1 drugs representing a significant breakthrough in treatment [2] - The collaboration is expected to set a benchmark in metabolic disease management, providing high-quality drug and professional services to more patients [2][3] - The deep cooperation between chain pharmacies and innovative drug companies enhances drug accessibility while optimizing product offerings and professional health services [4]

Core Viewpoint - The strategic cooperation agreement between Innovent Biologics and Eli Lilly has been effective since March 24, 2026, aimed at advancing new drug development in oncology and immunology, without involving equity transactions [1][3]. Group 1: Agreement Details - The agreement was initially announced on February 8, 2026, and is the seventh collaboration between the two companies, enhancing their long-term partnership to deliver innovative drugs to global patients [1][3]. - Innovent Biologics clarified that the agreement is not a merger or acquisition, emphasizing that it is solely focused on research collaboration and does not alter the company's independent operations or equity structure [1][3]. Group 2: Financial Aspects - Innovent Biologics will receive an upfront payment of $350 million, with the potential to earn up to approximately $8.5 billion in milestone payments related to research, regulatory, and commercialization achievements [2][4]. - The company retains all rights to the relevant projects in Greater China while Eli Lilly obtains exclusive global development and commercialization rights outside of this region [2][4]. Group 3: Company Background - Founded in 2011, Innovent Biologics focuses on the research, production, and sales of innovative drugs in major disease areas such as oncology, autoimmune diseases, metabolism, and ophthalmology [2][5]. - The company has 18 products approved for market, with 4 new drug molecules in Phase III or pivotal clinical studies, and an additional 15 new drug candidates in clinical research [2][5]. - Innovent Biologics has established over 30 strategic collaborations with international partners, including Eli Lilly, Roche, Takeda, Sanofi, Incyte, and MD Anderson Cancer Center [2][5].

Market Performance - A-shares halted their decline, with the Shanghai Composite Index rising by 1.78% to 3881.28 points, and the Shenzhen Component Index increasing by 1.43%[1] - The Hang Seng Index opened higher, gaining 2.79% to close at 25063.71 points, while the Hang Seng Technology Index surged by 2.51%[1] - The total market turnover in Hong Kong reached 3030.734 million HKD[1] Geopolitical Developments - President Trump hinted at a potential diplomatic breakthrough with Iran, suggesting that Iran has made a significant gesture related to the Strait of Hormuz, with negotiations ongoing[12] - The U.S. is reportedly seeking a one-month ceasefire to facilitate diplomatic discussions with Iran, proposing a 15-point plan to end the conflict[12] Economic Indicators - The S&P Global PMI indicated that U.S. business activity growth slowed to its lowest level in nearly a year, with input prices rising following the outbreak of the Iran conflict[12] - The composite output index fell to 51.4, with a reading above 50 indicating expansion, while input prices rose to their highest level since May[12] Investment Trends - China's sovereign wealth fund, CIC, is reportedly re-engaging with U.S. asset management firms, including Blackstone and TPG, after previously reducing exposure to the U.S.[12]